THE ECONOMIC BURDEN OF ANEMIA IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

Value Health, March 1, 2005; 8(2): 149-56.

Anemia is one of the most common hematologic complications of cancer and cytotoxic treatment. The economic burden associated with anemia in patients with malignancy has not yet been extensively studied.

Patients receiving chemotherapy within 6 months of initial cancer diagnosis were identified in a database of commercial health-care service claims and encounters. Patients with anemia were identified through a coded diagnosis of anemia, transfusion, or erythropoietin treatment. Exponential conditional mean models and a decomposition analysis were used to analyze mean 6-month health-care expenditures.

Twenty-six percent (26%) of 2760 cancer patients with recently diagnosed invasive cancer treated with chemotherapy had anemia. Mean (SD) 6-month unadjusted total expenditures were $62,499 ($78,016) for anemic patients and $36,871 ($52,308) for nonanemic patients (P < 0.0001), with inpatient services representing the largest cost differential between the groups. The adjusted mean 6-month expenditure for the average anemic patient receiving chemotherapy was $57,209. If anemic patients had the same average health status as nonanemic patients, their predicted 6-month expenditures would have been 19% lower ($46,237). Alternatively, if anemic patients had the same expenditure structure or parameter estimates as nonanemic patients, their predicted expenditures would have been 51% lower ($27,847). Thus, for any given health status, treating a patient who is anemic is associated with considerably higher expenditures.

Anemia among cancer patients receiving chemotherapy is associated with a substantial burden in terms of direct medical costs. Implications for the treatment of anemia are suggested by this research and should be confirmed in prospective studies.